---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-001252"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:40:11.413462+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bicycle reports 1 confirmed complete response in BT8009 Phase I; management restructured

## Summary
- BT8009 Phase I: 4/11 partial responses; one confirmed complete response (100% tumor reduction) at 5.0 mg/m2.
- Dose escalation continues at 7.5 mg/m2; interim Phase I results to be presented at a 2022 medical meeting.
- BT5528 Phase I/II on track to initiate expansion cohorts in 2022 with RP2D of 6.5 mg/m2 every-other-week.
- BT7480 Phase I dose escalation ongoing; four SITC posters on Bicycle TICAs including NK-cell-engaging molecule.
- Michael Skynner becomes CTO (new role); Alistair Milnes promoted to COO, both effective Jan 3, 2022.

## SEC filing metadata
- accession: 0001104659-22-001252
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/0001104659-22-001252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/tm221573d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-001252
- JSON: https://secwatch.observer/filing/0001104659-22-001252.json
- Plain text: https://secwatch.observer/filing/0001104659-22-001252.txt

## Key facts
- Executive change
  Alistair Milnes was appointed as Chief Operating Officer at BICYCLE THERAPEUTICS PLC.
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On January 5, 2022, Bicycle Therapeutics plc (the “Company”) announced the appointment of Alistair Milnes, age 48, as the Company’s Chief Operating Officer, effective as of January 3, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/0001104659-22-001252-index.htm
- Executive change
  Michael Skynner changed role as Chief Technology Officer at BICYCLE THERAPEUTICS PLC.
  - Action: transitioned to
  - Role: Chief Technology Officer
  source text: following the transition of Michael Skynner, Ph.D. to the newly-created role of Chief Technology Officer of the Company as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/0001104659-22-001252-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.